BASIC SCIENCE RESEARCH PROGRAM
Innovative Techniques Through Basic Science Research
The Basic Science Research Program (BSRP) focuses on defining prostate cancer-specific molecular alterations that would lead to better understanding of the causes of prostate cancer. Prostate cancer gene discovery and biology focused research efforts are complemented by collaborations from the CPDR's Clinical Research and Multicenter National Database programs, accelerating the evaluations of new biomarkers and therapeutic targets with potential in enhancing the management of prostate cancer.
The program is led by Dr. Shiv Srivastava, who is an internationally recognized leader in the field of cancer research. Strong collaborations with Dr. Isabell A. Sesterhenn from JPC (formerly AFIP) and the CPDR-Clinical Research Program at WRNMMC (formerly WRAMC) remains the mainstay of the highly productive translational research initiatives. Due to the reorganization of the AFIP as JPC, Dr. Sesterhenn's laboratory has been integrated within the CPDR-BSRP as of August 2011.
- Discovery of frequent and potentially causal prostate cancer gene alterations using cutting edge technologies and well annotated and precisely processed bio-specimens
- Evaluation of cancer biology of prostate cancer relevant genes or proteins using established and new experimental models
- Development of new molecular strategies for improving prostate cancer diagnosis (more cancer specific markers than PSA) and prognosis Contents are Proprietary and Provided for CPDR Scientific Advisory Committee Review Only 1: 5
- Delineation of hormonal mechanisms involved in prostate cancer onset or progression
- Development and evaluation of novel molecular therapeutic agents for prostate cancer
- Identification of molecular determinants of prostate cancer susceptibility in high-risk groups such as African-Americans
- Development and maintenance of long-term molecular specimen resources for translational investigations at CPDR and collaborations at other institutions
- Education and training of next generation of basic science and translational researchers in prostate cancer
Education and training of medical and graduate students, post-doctoral fellows, residents and visiting scientists in CaP research Two of the major activities of the BRP research program include investigator-initiated research and development of unique bio-resources critical for research at CPDR and in the CaP field.
September 29, 2014
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).
Read Full Article.
Read Publication - European Urology
Read the NOVEMEBR 2014 Newsletter